CellaVision AB
STO:CEVI
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SE |
|
CellaVision AB
STO:CEVI
|
3.8B SEK |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
132.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39B USD |
Loading...
|
Market Distribution
| Min | -2 025 693.8% |
| 30th Percentile | -1.8% |
| Median | 6% |
| 70th Percentile | 12.5% |
| Max | 10 459.2% |
Other Profitability Ratios
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for CellaVision AB is 26.5%, which is above its 3-year median of 24.6%.
Over the last 3 years, CellaVision AB’s Operating Margin has increased from 26.3% to 26.5%. During this period, it reached a low of 21.1% on Jun 30, 2023 and a high of 26.5% on Sep 30, 2025.
